New biopolymers for the treatment of respiratory conditions

We develop new biopolymers for the treatment of respiratory conditions.

Glycocore Pharma is a start-up committed to the development of pharmaceuticals based on the active principle HYLACH®.

GLYCOCORE

Therapeutic
areas

Idiopathic pulmonary fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a rare chronic and progressive lung disorder with high lethality and considerable morbidity.

Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a frequent disorder characterized by irreversible lung obstruction.

SARS-CoV-2 associated Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS) is a life-threatening condition caused by severe lung inflammation.

GLYCOCORE

Technology

Galectin-3

The Galectin family includes 15 protein members with a β-galactoside-binding domain and commonly expressed in several tissue types (Kyosov e Traber, 2012).

HYLACH

HYLACH® is a natural biopolymeric molecule composed by a hyaluronic acid chain conjugated with lactose derivative residues.